A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №2, 2026

more

A.I. Burnasyan  FMBC clinical bulletin. 2026 № 2

E.A. Praskurnichiy1,2, Y.D. Udalov2, Y.S. Kitayeva1, B.G. Yurgin2

Leukemias and Metabolic Syndrome: Clinical Features, Bidirectional Relationship

1Russian National Research Medical University named after. N. I. Pirogova,  Moscow, Russia

2International Office, State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russiа

Contact person: Kitaeva Julya Sergeevna: jkhema@yandex.ru

 

Abstract
Acute leukemias represent a group of malignant hematopoietic disorders characterized by the uncontrolled proliferation of abnormal cells. Within the overall incidence of hematologic malignancies, acute leukemias (both myeloid and lymphoblastic) constitute a significant proportion, occurring at an estimated frequency of approximately 4 cases per 100,000 adults for acute myeloid leukemia and 1.5 cases for acute lymphoblastic leukemia. Key indicators of treatment efficacy include complete remission and long-term survival.
Modern therapeutic strategies, encompassing polychemotherapy and hematopoietic stem cell transplantation (HSCT), have led to substantial improvements in the overall survival rates of patients with acute leukemia. However, the intensity of treatment is often accompanied by the development of various complications, among which metabolic disturbances are of particular clinical relevance. These alterations may present as both acute events (such as hyperglycemia and electrolyte imbalances) and delayed effects (including lipid metabolism disorders, osteopenic processes, and disruptions in endocrine regulation).
While the toxicity of antineoplastic therapy is widely discussed in the current literature, the specific features and dynamics of metabolic disturbances in adult patients with acute leukemia undergoing pathogenetic treatment (including HSCT) remain insufficiently studied. The absence of standardized diagnostic and monitoring algorithms for metabolic abnormalities at different stages of treatment complicates timely intervention and the prevention of severe complications.
Thus, the relevance of this topic is underscored by the need for systematic verification of metabolic disturbances throughout the disease course – from initial diagnosis to late post-treatment periods – which could enhance diagnostic and therapeutic processes, improve patient quality of life, and ultimately contribute to better prognostic outcomes.

Keywords: metabolic syndrome, dyslipidemia, acute leukemia, hematology, chemotherapy, bone marrow transplantation

For citation: Praskurnichiy EA, Udalov YD, Kitayeva YS, Yurgin BI. Leukemias and Metabolic Syndrome: Clinical Features, Bidirectional Relationship. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2026.2: 108-112. (In Russian) DOI: 10.33266/2782-6430-2026-2-108-112

 

REFERENCES

  1.  Anderson, M. A., Johnson, E. C., & Williams, C. D. (2021). The Interplay Between Metabolic Syndrome and Hematologic Malignancies: A Review. Blood Reviews, 48, 100795.
  2. Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7–30.
  3.  Monteiro, R., Azevedo, I., & Calhau, C. (2019). Metabolic Syndrome, Inflammation and Cancer: The Role of Adipokines and Cytokines. Inflammation Research, 68(7), 541–552.
  4. Saklayen, M. G. (2018). The Global Epidemic of the Metabolic Syndrome. Current Hypertension Reports, 20(2), 12.
  5. Nazarova, M. I., Sererbrovskaya, T. V., Karpova, O. V. (2019). Метаболический синдром: диагностические критерии и современные подходы к лечению. Терапевтический архив, 91(12), 45–53.
  6. O’Donnell, M. R., Abuty, N., Appelbaum, F. R., et al. (2018). Hematopoietic Cell Transplantation in the Modern Era: A Summary Statement from the 2017 Pan Pacific Lymphoma Conference. Biology of Blood and Marrow Transplantation, 24(11), e129–e134.
  7. Malard, F., & Mohty, M. (2020). New insights into the understanding of immune responses after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 55(4), 711–722.
  8. Malard F., Mohty M. New insights into the management of acute graft-versus-host disease. Blood, 2020; 135(9): 687–694.
  9. Froehlich, G. M., et al. (2019). Obesity and Ventricular Arrhythmias: A Meta-analysis of Adiposity and Ventricular Tachyarrhythmias. Obesity Reviews, 20(6), 865–868.
  10. Hashimoto S., et al. Genetic predisposition to steroid response in hematologic cancers. Haematologica, 2019; 104(9): 1778–1788.
  11. Guseva, M. A., Kotelnikov, G. P., Volkova, I. A. (2021). Acute Leukemias: Current Trends in Pathogenesis and Therapy. Hematology and Transfusiology 66(1), 15–29.
  12. Chang J., et al. Thyroid dysfunction and hyperlipidemia in patients with chronic leukemia receiving chemo- and targeted therapy. Thyroid, 2019; 29(11): 1537–1545.
  13. NCCN Guidelines. Management of Immunosuppressive Agents in Hematologic Malignancies, version 3.2023. National Comprehensive Cancer Network; 2023.
  14. Mashhadi M.A., et al. Nutritional intervention and mortality in hematologic cancer patients receiving chemotherapy: a meta-analysis. Nutrition, 2020; 74: 110751.
  15. Froehlich E.V., et al. Glucocorticoid-induced metabolic complications in hematologic malignancies: a clinical overview. Blood Rev, 2019; 37: 100584.
  16. Karim E., et al. Hepatoprotective and lipid-lowering strategies in patients under immunosuppressive regimens: a systematic review. Transplant Rev (Orlando), 2021; 35(2): 100579.
  17. Grignoli E., et al. Corticosteroid therapy in chronic hematological disorders: balancing efficacy and metabolic side effects. Leukemia Research, 2022; 117: 106893.
  18. Chung T., et al. Inflammatory markers and cachexia in leukemia patients: a prospective analysis. Clin Nutr, 2022; 41(3): 672–680.
  19. Przepiorka D., et al. Guidelines for personalized conditioning regimens in hematopoietic cell transplantation. Bone Marrow Transplant, 2021; 56(9): 2200–2209.
  20. Park H., et al. Cardiometabolic monitoring in adult patients undergoing hematopoietic cell transplantation: recommended strategies. J Oncol, 2021; 2021: 8876542.
  21. Park S., et al. Multidisciplinary approach to metabolic syndrome in hematopoietic stem cell transplantation survivors. Transplant Cell Ther, 2021; 27(9): 777.e1–777.e7.
  22. Jia W., et al. Gut microbiome and anticancer therapy-related toxicity. Cancer Lett, 2020; 482: 50–57.
  23. Wang Y., et al. Microbial modulation of immunosuppressive treatments in allogeneic hematopoietic stem cell transplantation. Cell Host Microbe, 2021; 29(5): 755–767.
  24. Sakamoto K., et al. Subclinical hypothyroidism in leukemia patients: does levothyroxine improve outcomes? Endocr Pract, 2018; 24(8): 765–772.

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 23.11.2025. Accepted for publication: 25.12.2025

© 2026 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top